ProCE Banner Activity

Slideset: Pharmacotherapy of Schizophrenia

Slideset Download
This presentation on pharmacotherapy of schizophrenia will review the role of shared decision-making, considerations in balancing efficacy and tolerability, the role of maintenance treatment, whether long-acting formulations help in reducing relapse risk, and when clozapine is indicated.

Released: December 08, 2021

Expiration: December 07, 2022

No longer available for credit.
Begin Activity

Share

Faculty

John M. Kane

John M. Kane, MD

Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell  
Co-Director
Institute for Behavioral Science, Feinstein Institutes for Medical Research
Northwell Health
New York, New York

 

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Intra Cellular Therapies

Faculty Disclosure

Primary Author

John M. Kane, MD

Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell  
Co-Director
Institute for Behavioral Science, Feinstein Institutes for Medical Research
Northwell Health
New York, New York

 

John M. Kane, MD, has disclosed that he has received funds for research support from H. Lundbeck, Janssen, and Otsuka; has received consulting fees from Alkermes, Allergan, Dainippon Sumitomo, H. Lundbeck, Intra-Cellular Therapies, Janssen, LB Pharmaceuticals, Lyndra, Merck, Neurocrine Biosciences, Otsuka, Reviva, Roche, Saladex, Sunovion, Takeda, and Teva; has ownership interest in LB Pharmaceuticals, Merck, Minerva, and North Shore Therapeutics; and has received fees for non-CME/CE services from Dainippon Sumitomo, H. Lundbeck, Janssen, and Otsuka.